Collaborative Working

Daiichi-Sankyo

Executive Summary

Project title	Capture AF: Development & implementation of a primary care AF hub
Project Partners	Daiichi Sankyo UK Ltd NHS Royal Brompton & Harefield Hospitals The Confederation Hillingdon CIC
Start - Finish date	June 2023 – July 2025
Project Support	Daiichi Sankyo UK Ltd financial contribution £241,735.34 NHS Royal Brompton & Harefield Hospitals and Hillingdon CIC Indirect contribution £252,032.24

This summary has been written by Daiichi Sankyo with consultation and approval from the Collaborative Working Group.

Project summary

The aim of this project is to set up a primary care CVD hub in LB of Hillingdon covering all six PCN's (Colne Union, Synergy, North Connect, Hayes & Harlington, Long Lane, & Metrocare) to support a 16 month two-strand project focused on:

1. Targeted detection of undiagnosed AF: proactive detection of undiagnosed AF through a minimum of 30 Community Pharmacists who will case find selected patients (approx. 1.33 per pharmacist per week) from their store's footfall e.g., prescription collection. These patients will be selected from those that are 65+ with risk factors e.g., hypertension and invited to be case found using a 1-lead ECG KardiaMonitor (AliveCor). Suspected AF cases or inconclusive results will be referred to the Primary Care AF Hub (staffed by the two dedicated advanced clinical pharmacists) via PharmOutcomes for ECG diagnosis confirmation. This AF HUB will be run across two sites with secondary care support from Harefield Hospital. Forecast: 2666 patients selected for case finding over 16 months. We forecast detecting AF in 2.0% of those tested based on results from the externally funded Capture AF service based in Hillingdon and led by Harefield Hospital which ran over a 1.5 year period between a 2017 and 2021. Community pharmacists in Hillingdon were trained to deliver opportunistic targeted AF detection using KardiaMobile monitors. 2566 people were reviewed, and 52 people were newly diagnosed with AF (2% detection rate)

2. Protection & Perfection for diagnosed AF patients: Proactive review of approx. 5000 patients on GP registers with diagnosed AF. The two dedicated advanced clinical pharmacists reviewing patients who require; bleeding & strokes assessments, initiating anticoagulation and anticoagulation optimisation. Per annum we forecast from local data (UCLP AF Toolkit) that

5% of this population per annum or 333 patients total over 16 months requiring bleeding and stroke assessments & 6% per annum or 400 patients total starting medications. With further patients requiring other medications optimised.

Outcomes: From the patients treated in the project, we estimate potentially preventing 37 strokes and 10 deaths over the 16-month period[1].

We aim to create proof-of-concept for service both for patient benefits and financial savings with North West London wide roll-out within 3-4 years of pilot wrap-up. The wider roll out is not part of this collaborative working project.

Update April 2026: Processing of the outcome data is still underway and is taking longer than anticipated. DSUK remains committed to publishing the results at the earliest opportunity.

Expected benefits to patients, the NHS & Daiichi-Sankyo

Expected benefits for the patient:

- Asymptomatic and symptomatic patients with no diagnosis will receive a diagnosis, reducing chances of either a stroke or wider symptoms
- Patients with an existing diagnosis will receive better care reducing their chances of strokes or other symptoms
- Improved patient experience by accessing AF diagnosis and treatment options closer to home
- Ensuring access to both pharmacological and non-pharmacological interventions in a timely manner to mitigate risk of complications

Expected benefits for the NHS organisation:

- For The Confederation and Royal Brompton and Harefield Hospitals this project meets our aim of improving healthcare for our patients through providing more timely access to care and enhancing patient care
- For the NHS this project would not only deliver significant patient benefits but financial savings. This will support financial stability in the primary care setting and allow expansion of the service post project

Expected benefits for Daiichi Sankyo:

- Improve management and treatment of patients with atrial fibrillation by working in partnership with the NHS
- Improve Daiichi Sankyo's reputational profile amongst local and national stakeholders
- It is anticipated as part of the project that more patients may be treated with a pharmaceutical product. This may include but is not exclusive to products manufactured by Daiichi Sankyo UK Ltd
- Project may provide a future publication with Daiichi Sankyo in partnership with NHS organization

1. The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke (sagepub.com) Accessed Feb 2023